全文获取类型
收费全文 | 46534篇 |
免费 | 4253篇 |
国内免费 | 2368篇 |
专业分类
耳鼻咽喉 | 553篇 |
儿科学 | 679篇 |
妇产科学 | 558篇 |
基础医学 | 5434篇 |
口腔科学 | 825篇 |
临床医学 | 5359篇 |
内科学 | 6772篇 |
皮肤病学 | 888篇 |
神经病学 | 2417篇 |
特种医学 | 1981篇 |
外国民族医学 | 7篇 |
外科学 | 4476篇 |
综合类 | 7243篇 |
现状与发展 | 11篇 |
一般理论 | 4篇 |
预防医学 | 3725篇 |
眼科学 | 807篇 |
药学 | 5072篇 |
34篇 | |
中国医学 | 2816篇 |
肿瘤学 | 3494篇 |
出版年
2024年 | 143篇 |
2023年 | 572篇 |
2022年 | 1493篇 |
2021年 | 2067篇 |
2020年 | 1501篇 |
2019年 | 1319篇 |
2018年 | 1441篇 |
2017年 | 1458篇 |
2016年 | 1558篇 |
2015年 | 2315篇 |
2014年 | 2811篇 |
2013年 | 3059篇 |
2012年 | 4294篇 |
2011年 | 4524篇 |
2010年 | 3241篇 |
2009年 | 2573篇 |
2008年 | 3032篇 |
2007年 | 2931篇 |
2006年 | 2540篇 |
2005年 | 2203篇 |
2004年 | 1686篇 |
2003年 | 1575篇 |
2002年 | 1357篇 |
2001年 | 915篇 |
2000年 | 690篇 |
1999年 | 444篇 |
1998年 | 264篇 |
1997年 | 224篇 |
1996年 | 165篇 |
1995年 | 145篇 |
1994年 | 128篇 |
1993年 | 72篇 |
1992年 | 88篇 |
1991年 | 74篇 |
1990年 | 45篇 |
1989年 | 39篇 |
1988年 | 31篇 |
1987年 | 23篇 |
1986年 | 17篇 |
1985年 | 12篇 |
1984年 | 10篇 |
1983年 | 7篇 |
1982年 | 4篇 |
1981年 | 6篇 |
1980年 | 4篇 |
1979年 | 21篇 |
1976年 | 4篇 |
1970年 | 4篇 |
1969年 | 6篇 |
1968年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 10 毫秒
31.
苯丙胺类兴奋剂(amphetamine-type stimulants,ATS)是21世纪主要流行滥用的药物之一,目前社会上流行的"冰毒","摇头丸"等属于此类毒品,主要有甲基苯丙胺(methamphetamine,METH),亚甲基二氧基甲基苯丙胺(MDMA)等.在我国,此类毒品无论是在舞厅、迪吧或其它公共娱乐场所和地下色情场所等都很容易获得,导致滥用人群日益扩大[1],影响社会治安和社会稳定.虽然世界各国在药物滥用防治工作中投入了大量的人力、物力、财力,但收效甚微,对ATS依赖者目前治疗多采用强制戒毒、对症治疗和辅以心理治疗等方法,但治疗时间长,复吸率高[1-4],对于高危人群目前还没有一种有效的预防手段.检测ATS多用高效液相色谱(HPLC)、气相色谱-质谱联用(GC-MS)、薄层色谱(TLC)等[2]方法,其设备昂贵,难以开展现场检测,应用范围受限,并不适合于现场快速便捷检测,因而探索对ATS更有效的预防、治疗方法和更便捷的现场检测方法,极具现实意义. 相似文献
32.
螺旋CT三期扫描对肝纤维化诊断价值研究 总被引:5,自引:1,他引:4
目的探讨螺旋CT三期扫描对肝纤维化的诊断价值。方法对66例经肝穿刺活检病理证实的慢性乙型肝炎肝纤维化患者组和42例正常对照组进行螺旋CT三期增强扫描。根据纤维化程度分期进行影像资料和相关指标的统计分析。结果肝左叶增大,肝表面形态及肝实质密度的改变,脾脏增大,门静脉增宽和侧枝循环的建立等影像学改变,随着肝纤维化严重程度的加重而有统计学差异。本研究显示57例肝纤维化患者螺旋CT三期扫描诊断肝纤维化52例,敏感性91.2%,特异性77.8%。各期肝纤维化分期准确28例,准确率49.1%;准确判断轻度纤维化(S1、S2)或重度纤维化(S3、S4)44例,准确率77.2%,诊断早期肝硬化16例,准确率84.2%。结论螺旋CT三期扫描能判断肝纤维化的程度,而且是动态观察肝纤维化的病程演进和临床随访的有效手段。 相似文献
33.
目的观察急性冠状动脉综合征患者介入治疗后血小板活化指标CD62p、CD63及糖蛋白Ⅱb/Ⅲa受体复合物及内皮功能的改变。方法60例急性冠状动脉综合征患者在冠状动脉介入术前和术后即刻以及次日采用流式细胞仪检测血小板活化指标CD62p、CD63及糖蛋白Ⅱb/Ⅲa受体复合物;双抗体夹心固相酶联免疫吸附试验测定血浆假血友病因子的表达水平;放射免疫测定法测定血浆内皮素1表达水平;酶法测定血浆一氧化氮的含量;彩色多谱勒超声诊断仪测量内皮依赖性血管舒张功能。选择健康体检者和稳定型心绞痛患者各30例作对照,观察急性冠状动脉综合征患者冠状动脉介入前后指标的变化并与对照组比较。结果与健康对照组和稳定型心绞痛组比,急性冠状动脉综合征组CD62p、CD63及糖蛋白Ⅱb/Ⅲa受体复合物明显增高(P<0.05或0.01);急性冠状动脉综合征患者介入术后即刻CD62p、CD63和糖蛋白Ⅱb/Ⅲa受体复合物与术前相比明显增高(P<0.01),但术后24h较术前无明显变化(P>0.05)。与健康对照组和稳定型心绞痛组比,急性冠状动脉综合征组假血友病因子、内皮素1的表达水平明显增高(P<0.01),内皮依赖性血管舒张功能和一氧化氮降低(P<0.05或<0.01);急性冠状动脉综合征患者介入术后即刻血浆假血友病因子和内皮素1水平升高(P<0.05或P<0.01),内皮依赖性血管舒张功能和一氧化氮水平降低(P<0.05),且介入术后24h假血友病因子水平也较术前升高(P<0.05),内皮依赖性血管舒张功能降低(P<0.05),但内皮素1和一氧化氮水平与术前差异无显著性(P>0.05)。结论血小板活化和内皮功能的损伤在急性冠状动脉综合征发生和发展过程中起重要的作用,冠状动脉介入术后血管内皮受到一定损伤,血小板有一定程度的激活。 相似文献
34.
Molecular determinants of cetuximab efficacy. 总被引:17,自引:0,他引:17
Daniel Vallb?hmer Wu Zhang Michael Gordon Dong Yun Yang Jim Yun Oliver A Press Katrin E Rhodes Andy E Sherrod Syma Iqbal Kathleen D Danenberg Susan Groshen Heinz-Josef Lenz 《Journal of clinical oncology》2005,23(15):3536-3544
PURPOSE: To investigate whether mRNA expression levels of cyclin D1 (CCND1), cyclooxygenase 2 (Cox-2), epidermal growth factor receptor (EGFR), interleukin 8 (IL-8), and vascular endothelial growth factor (VEGF), all members of the EGFR signaling pathway, are associated with clinical outcome in patients with EGFR-expressing metastatic colorectal cancer (CRC) treated with cetuximab. PATIENTS AND METHODS: Thirty-nine patients with metastatic CRC, refractory to both irinotecan and oxaliplatin, were enrolled on IMCL-0144 and treated with single-agent cetuximab. The intratumoral mRNA levels of CCND1, Cox-2, EGFR, IL-8, and VEGF were assessed from paraffin-embedded tissue samples using laser-capture microdissection and quantitative real-time polymerase chain reaction. RESULTS: There were 21 women and 18 men with a median age of 64 years (range, 35 to 83 years). Higher gene expression levels of VEGF were associated with resistance to cetuximab (P = .038; Kruskal-Wallis test). The combination of low gene expression levels of Cox-2, EGFR, and IL-8 was significantly associated with overall survival (13.5 v 2.3 months; P = .028; log-rank test). Both findings were independent of skin toxicity that was itself significantly correlated to survival. Patients with a lower mRNA amount of EGFR had a longer overall survival compared with patients that had a higher mRNA amount (7.3 v 2.2 months; P = .09; log-rank test). Patients with lower expression of Cox-2 had a significantly higher rate of grade 2 to 3 skin reactions under cetuximab treatment. CONCLUSION: This pilot study suggests that gene expression levels of Cox-2, EGFR, IL-8, and VEGF in patients with metastatic CRC may be useful markers of clinical outcome in single-agent cetuximab treatment. 相似文献
35.
Sa-Yoon Kang Jung Seok Lee Jay Chol Choi Ji-Hoon Kang 《JOURNAL OF CLINICAL NEUROLOGY》2007,3(3):158-160
A small proportion of thymoma patients without myasthenia gravis (MG) have been observed to develop MG after total removal of the thymoma. However, the underlying cause is not yet known due to the rarity of postoperative MG patients. We report a 39-year-old man in whom MG appeared after surgical removal of a thymoma. Computed tomography and magnetic resonance imaging showed no signs of recurrent or metastatic thymoma. Administration of pyridostigmine bromide resulted in the prompt improvement of myasthenic symptoms. Our observations indicate that postoperative follow-up care with monitoring of possible postoperative MG is necessary after resecting a thymoma. 相似文献
36.
目的探讨两种单静脉入路法和动静脉双入路法治疗PDA各自的优缺点及最佳适应症,为PDA患者选择合理介入治疗方法提供依据。方法103例PDA患者经三种不同介入方法治疗,其中单静脉入路超声法37例,单静脉入路造影法14例,动静脉双入路法52例。PDA的位置、形态、大小经不同方法观察,单静脉超声法经超声观察,单静脉造影法在PDA内或降主动脉近PDA口外造影观察,动静脉双入路在主动脉弓降部侧位造影观察。选择合适型号的Amplatzer伞经股静脉建立的轨道进行封堵。术后15 min经胸超声及心脏听诊判断有无分流。术前、术后均行血流动力学测定,术后3 d、1个月复查超声心动图,观察大动脉水平有无分流及动脉导管未闭再通。结果103例患者全部一次封堵成功,技术成功率100%。术中操作平均透视时间(10.45±4.35)min,心导管检查测肺动脉收缩压由术前轻度增高[(33.2±3.11)mmHg]降为正常[(22.03±5.3)mmHg]。术后即刻所有患者心前区双期连续性杂音消失,术后无残余分流,无任何并发症发生,随访1个月未发生动脉水平分流及动脉导管再通。结论单静脉入路Amplatzer封堵器治疗动脉导管未闭简化了手术程序,不用或减少造影剂用量,缩短了操作透视时间,手术成功率高,疗效可靠,值得推广应用。 相似文献
37.
Eric Lim Ziad Ali Ayyaz Ali Reza Motalleb-Zadeh Christopher Jackson Seok Ling Ong James Halstead Linda Sharples Jayan Parameshwar John Wallwork Stephen R Large 《The Journal of heart and lung transplantation》2005,24(8):983-989
BACKGROUND: To ascertain survival of ischemic advanced heart failure patients by treatment allocation, we examined the outcome of transplant assessment patients allocated to medical therapy, high-risk conventional surgery, or transplantation. METHODS: Patients were identified from the Papworth transplant database and excluded if primary etiology was not ischemic. Grouping was undertaken according to treatment allocation at initial assessment, and analysis was performed by intention to treat. Survival was computed from the time of assessment and Cox regression used to stratify patients according risk with the Heart Failure Survival Score. RESULTS: From May 1993 to September 2001, a total of 755 patients were admitted for transplant assessment, with 348 (46.1%) identified as having heart failure of ischemic origin. Variables required for calculation of the Heart Failure Survival Score was available in 273 patients (78.4%), and 20 patients (7.3%) were lost to follow-up. Of the remaining 253 patients, 89 (35.2%) were allocated to medical therapy, 32 (12.6%) to surgery, and 132 (52.2%) to transplantation. The relative risk (95% confidence limit) of death compared with medical therapy was 0.62 (0.28, 1.40) for surgery and 0.38 (0.24, 0.61) for transplantation in medium- to high-risk patients. For low-risk patients, the relative risks for death compared with medical therapy were 1.87 (0.63, 5.60) for surgery and 1.97 (0.79, 4.96) for transplantation. CONCLUSIONS: Transplantation improved survival of medium- and high-risk patients compared with medical therapy. In the low-risk group, this was not evident. However, repeated assessment of risk is required because the hazard for death rises steadily after the third year in these patients. 相似文献
38.
39.
40.
本文建立了血清、尿中SMZ和TMP的薄层扫描定性定量检测方法。血清和尿中SMZ的线性检测范围为4~128μg/ml,最小检出浓度为1.6μg/ml;TMP的线性检测范围为1~32μg/ml,最小检出浓度为0.8μg/ml。 相似文献